Intersection of FcγRIIB, the microbiome, and checkpoint inhibitors in antitumor immunity

Autor:	Mandy L. Ford, Kirsten M Baecher
Rok vydání:	2021
Předmět:	Cancer Research Antitumor immunity Immune checkpoint inhibitors Immunology Cancer Inflammation Context (language use) Biology medicine.disease Oncology medicine T cell immunity Immunology and Allergy Microbiome medicine.symptom Receptor
Zdroj:	Cancer Immunology, Immunotherapy. 70:3397-3404
ISSN:	1432-0851 0340-7004
DOI:	10.1007/s00262-021-03004-4
Popis:	Fc receptors (FcRs) and the microbiome are both known to have an effect on the development and progression of cancers. Checkpoint inhibitors are a novel class of therapeutics which are used to combat cancer and are integrally linked to both FcRs and the microbiome. The use of checkpoint inhibitors has grown exponentially over the past decade, although many host factors affect both the efficacy and the safety of these therapeutics. Some of these host factors, including the microbiome and the expression of FcRs, are currently being investigated. Here we discuss the current understanding of FcRs (particularly the inhibitory FcγRIIB) and the microbiome in context of T cell immunity, inflammation, cancer, and checkpoint inhibition.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::8bb92b3b98c572b4124858db5d18ebab https://doi.org/10.1007/s00262-021-03004-4 Zobrazit plný text záznamu Full text from SpringerLink